Pharmacyte Biotech Inc (PMCB)

$0.98 +0.02 (1.78%)
Market Cap 6.52M
Revenue (ttm) 0.00
Net Income (ttm) 30.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 35,600
Avg Vol 115,706
Day's Range N/A - N/A
Shares Out 6.80M
Stochastic %K 42%
Beta -0.05
Analysts Strong Buy
Price Target N/A

Company Profile

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other soli...

Industry: Biotechnology
Sector: Healthcare
Phone: 917-595-2850
Fax: 917-595-2851
Address:
3960 Howard Hughes Parkway, Suite 500, Las Vegas, United States
BHWinehouse
BHWinehouse Oct. 24 at 4:12 PM
$QCLS Yep, that's it! Nothing to do with obtaining exclusive rights to Lightsolver photonics tech saving companies like $MARA 90% on energy or the fact they have MYMD-1 that is ready to enter Ph2 clinical trials which will most likely be sold to $PMCB since they already have $7M invested in it and we the same "ceo". Nothing really to see here....
0 · Reply
Pistol_Pete_P
Pistol_Pete_P Oct. 21 at 5:30 AM
$PMCB scam
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 15 at 2:16 PM
$QCLS watching $PMCB ehom I believe will acquire all of WCLS bio assets The cash from the bio assets will fund the new $TAO.X $TAOX crypto strategy @jaltucher wheres the news man. It’s long overdue.
0 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 14 at 9:39 PM
$PMCB
0 · Reply
Peaceouty
Peaceouty Oct. 14 at 8:55 PM
$SBLX we are owned by a hedge fund, and that explains the harsh price control we’ve seen today. Same with $PMCB
0 · Reply
Peaceouty
Peaceouty Oct. 14 at 8:45 PM
$SBLX Our ceo is also the CEO of $PMCB! Woot woot! Also he’s been the assistant press secretary of the President!
1 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 6:07 PM
$QCLS $PMCB
1 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 4:07 PM
$QCLS $PMCB
0 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 1:16 PM
$QCLS Also keep in mind, both $QCLS and $PMCB have meetings in the following weeks...
0 · Reply
BurchhausenJj
BurchhausenJj Oct. 14 at 11:56 AM
$PMCB $QCLS $TAOX @BHWinehouse @Dat1099Boi yes all of that is imminent And @jaltucher as a major player This (QCLS) is a fantastic set up. Their bio assets will bring in cash. 💷 💰
0 · Reply
Latest News on PMCB
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

Sep 2, 2025, 9:20 AM EDT - 7 weeks ago

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

Aug 20, 2025, 9:15 AM EDT - 2 months ago

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

Aug 18, 2025, 9:15 AM EDT - 2 months ago

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

Nov 15, 2023, 8:30 AM EST - 2 years ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

FEMY

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Oct 31, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

PharmaCyte Biotech Announces Final Results of Tender Offer

Jun 15, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Announces Final Results of Tender Offer

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

May 11, 2023, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Feb 2, 2023, 9:00 AM EST - 2 years ago

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Oct 7, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Aug 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Jul 28, 2022, 12:49 PM EDT - 3 years ago

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Jul 28, 2022, 9:00 AM EDT - 3 years ago

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 21, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 19, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 11, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 11, 2022, 6:00 AM EDT - 3 years ago

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 3:16 PM EDT - 3 years ago

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jul 5, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Jun 23, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 13, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jun 9, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

Jun 8, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

Jun 2, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 23, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

May 11, 2022, 9:00 AM EDT - 3 years ago

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 27, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 19, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 13, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Apr 5, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 22, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Mar 16, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 22, 2022, 9:00 AM EST - 3 years ago

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Feb 14, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Jan 7, 2022, 2:59 AM EST - 4 years ago

Is This A Good Time To Invest In PharmaCyte?

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

Jan 6, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

Jan 4, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

Dec 28, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

Dec 15, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

Dec 8, 2021, 10:16 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Nov 30, 2021, 1:05 AM EST - 4 years ago

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Nov 12, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

Sep 27, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 21, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Why Are PharmaCyte Shares Moving Higher On Thursday?

Sep 16, 2021, 1:51 PM EDT - 4 years ago

Why Are PharmaCyte Shares Moving Higher On Thursday?

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 16, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

Sep 9, 2021, 8:57 AM EDT - 4 years ago

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Sep 8, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

BHWinehouse
BHWinehouse Oct. 24 at 4:12 PM
$QCLS Yep, that's it! Nothing to do with obtaining exclusive rights to Lightsolver photonics tech saving companies like $MARA 90% on energy or the fact they have MYMD-1 that is ready to enter Ph2 clinical trials which will most likely be sold to $PMCB since they already have $7M invested in it and we the same "ceo". Nothing really to see here....
0 · Reply
Pistol_Pete_P
Pistol_Pete_P Oct. 21 at 5:30 AM
$PMCB scam
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 15 at 2:16 PM
$QCLS watching $PMCB ehom I believe will acquire all of WCLS bio assets The cash from the bio assets will fund the new $TAO.X $TAOX crypto strategy @jaltucher wheres the news man. It’s long overdue.
0 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 14 at 9:39 PM
$PMCB
0 · Reply
Peaceouty
Peaceouty Oct. 14 at 8:55 PM
$SBLX we are owned by a hedge fund, and that explains the harsh price control we’ve seen today. Same with $PMCB
0 · Reply
Peaceouty
Peaceouty Oct. 14 at 8:45 PM
$SBLX Our ceo is also the CEO of $PMCB! Woot woot! Also he’s been the assistant press secretary of the President!
1 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 6:07 PM
$QCLS $PMCB
1 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 4:07 PM
$QCLS $PMCB
0 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 1:16 PM
$QCLS Also keep in mind, both $QCLS and $PMCB have meetings in the following weeks...
0 · Reply
BurchhausenJj
BurchhausenJj Oct. 14 at 11:56 AM
$PMCB $QCLS $TAOX @BHWinehouse @Dat1099Boi yes all of that is imminent And @jaltucher as a major player This (QCLS) is a fantastic set up. Their bio assets will bring in cash. 💷 💰
0 · Reply
BHWinehouse
BHWinehouse Oct. 14 at 11:03 AM
$QCLS $PMCB What might be in the works? $QCLS will sell MYMD-1 to $PMCB in the next few weeks. Shortly after is when our first big crypto related announcement takes place. Remember, Joshua Silverman!
2 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 7 at 1:04 PM
$PMCB
0 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 4 at 11:18 PM
$PMCB
0 · Reply
BHWinehouse
BHWinehouse Oct. 3 at 1:15 PM
$QCLS $PMCB MYMD-1 PEER REVIEWED and for sale!! https://news.biobuzz.io/2025/07/16/mymd-pharmaceuticals-announces-publication-of-phase-1-data-for-oral-tnf-alpha-inhibitor-mymd-1-in-peer-reviewed-journal-drug-research/?utm_source=chatgpt.com
0 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 3 at 12:55 PM
$PMCB
0 · Reply
BHWinehouse
BHWinehouse Oct. 2 at 11:09 PM
$QCLS $PMCB Could be closer than we think... MYMD-1 will be sold, it's just a matter of when and for how much. AND oh yeah, the whole Lightsavor thing!
0 · Reply
Dfastpitchchic5
Dfastpitchchic5 Oct. 1 at 8:28 PM
$PMCB
0 · Reply
BHWinehouse
BHWinehouse Oct. 1 at 1:06 PM
$QCLS $PMCB i feel a deal is close
0 · Reply
BHWinehouse
BHWinehouse Sep. 30 at 2:53 PM
$QCLS $PMCB I think JJ is closer to right than wrong on this one: PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company’s most recent 10K. With the addition of the $7 million in proceeds from this financing, the Company’s balance sheet has been further strengthened, providing significant financial flexibility to support its ongoing business initiatives and strategic growth opportunities.
1 · Reply
Dfastpitchchic5
Dfastpitchchic5 Sep. 29 at 1:35 PM
$PMCB
0 · Reply
TruthTrader
TruthTrader Sep. 26 at 2:20 AM
$ORBS $PMCB $WLDS pmcb held it for years when it was trading 3 dollars. Snails in my back yard saw more action than this stock. The defifinition of dead money. Company issued shares/placement so that management could get paid for years to come. They said they cared about shareholder value but did nothing. $QURE take note here. I dumped at a loss. I will never buy a biotech stock again. Never!
1 · Reply
ChartChartist
ChartChartist Sep. 24 at 4:46 PM
$PMCB looking for a nice one
0 · Reply